A citation-based method for searching scientific literature

L A Leiter, H Teoh, O Mosenzon, A Cahn, B Hirshberg, C A M Stahre, J B L Hoekstra, M Alvarsson, K Im, B M Scirica, D L Bhatt, I Raz. Diabetes Obes Metab 2016
Times Cited: 19







List of co-cited articles
142 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
63

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
57

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
52

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
42

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
560
36

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
31

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
31

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.
Michael A Nauck, Thomas Jon Jensen, Carina Rosenkilde, Salvatore Calanna, John B Buse. Diabetes Care 2018
30
31

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
422
26

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
26

Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues.
Ben-Dong Chen, Wen-Chao Zhao, Jian-Da Dong, Hui Sima. Mol Biol Rep 2014
9
55

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis.
M Marzioni, G Alpini, S Saccomanno, C Candelaresi, J Venter, C Rychlicki, G Fava, H Francis, L Trozzi, A Benedetti. Gut 2009
48
26

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Itamar Raz, Deepak L Bhatt, Boaz Hirshberg, Ofri Mosenzon, Benjamin M Scirica, Amarachi Umez-Eronini, KyungAh Im, Christina Stahre, Alona Buskila, Nayyar Iqbal,[...]. Diabetes Care 2014
44
21

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
G Schernthaner, S Durán-Garcia, M Hanefeld, G Langslet, L Niskanen, C J Östgren, E Malvolti, E Hardy. Diabetes Obes Metab 2015
45
21


Cancer recording and mortality in the General Practice Research Database and linked cancer registries.
Rachael Boggon, Tjeerd P van Staa, Michael Chapman, Arlene M Gallagher, Tarek A Hammad, Mike A Richards. Pharmacoepidemiol Drug Saf 2013
105
21

Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.
Angelo Pietro Femia, Laura Raimondi, Giulia Maglieri, Maura Lodovici, Edoardo Mannucci, Giovanna Caderni. Int J Cancer 2013
43
21

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
M Gokhale, J B Buse, C L Gray, V Pate, M A Marquis, T Stürmer. Diabetes Obes Metab 2014
53
21

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
21

An updated review on cancer risk associated with incretin mimetics and enhancers.
Chin-Hsiao Tseng, Kuo-Yang Lee, Farn-Hsuan Tseng. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2015
33
21

Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis.
Marco Marzioni, Gianfranco Alpini, Stefania Saccomanno, Cinzia Candelaresi, Juliet Venter, Chiara Rychlicki, Giammarco Fava, Heather Francis, Luciano Trozzi, Shannon Glaser,[...]. Gastroenterology 2007
57
21

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Devin Abrahami, Antonios Douros, Hui Yin, Oriana Hy Yu, Jean-Luc Faillie, François Montastruc, Robert W Platt, Nathaniel Bouganim, Laurent Azoulay. BMJ 2018
26
21

Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Ming Zhao, Jiayi Chen, Yanyan Yuan, Zuquan Zou, Xiaolong Lai, Daud M Rahmani, Fuyan Wang, Yang Xi, Qin Huang, Shizhong Bu. Sci Rep 2017
24
21


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Jacob A Udell, Deepak L Bhatt, Eugene Braunwald, Matthew A Cavender, Ofri Mosenzon, Ph Gabriel Steg, Jaime A Davidson, Jose C Nicolau, Ramon Corbalan, Boaz Hirshberg,[...]. Diabetes Care 2015
104
15

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
507
15


Validity of the general practice research database.
Susan S Jick, James A Kaye, Catherine Vasilakis-Scaramozza, Luis A Garcia Rodríguez, Ana Ruigómez, Christoph R Meier, Raymond G Schlienger, Corri Black, Hershel Jick. Pharmacotherapy 2003
479
15

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
786
15

Clinical information for research; the use of general practice databases.
R Lawrenson, T Williams, R Farmer. J Public Health Med 1999
213
15

Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.
S Schneeweiss, J D Seeger, M Maclure, P S Wang, J Avorn, R J Glynn. Am J Epidemiol 2001
588
15

Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Lawrence A Leiter, Hwee Teoh, Eugene Braunwald, Ofri Mosenzon, Avivit Cahn, K M Prasanna Kumar, Alena Smahelova, Boaz Hirshberg, Christina Stahre, Robert Frederich,[...]. Diabetes Care 2015
54
15

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
M B Rehman, B V Tudrej, J Soustre, M Buisson, P Archambault, D Pouchain, H Vaillant-Roussel, F Gueyffier, J-L Faillie, M-C Perault-Pochat,[...]. Diabetes Metab 2017
65
15

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
15

Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Juan Camilo Arjona Ferreira, Michel Marre, Nir Barzilai, Hua Guo, Gregory T Golm, Christine McCrary Sisk, Keith D Kaufman, Barry J Goldstein. Diabetes Care 2013
117
15



Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Fan Yang, Yuta Takagaki, Yasuo Yoshitomi, Takayuki Ikeda, Jinpeng Li, Munehiro Kitada, Asako Kumagai, Emi Kawakita, Sen Shi, Keizo Kanasaki,[...]. Cancer Res 2019
50
15

On the origin of serum CD26 and its altered concentration in cancer patients.
Oscar J Cordero, Francisco J Salgado, Montserrat Nogueira. Cancer Immunol Immunother 2009
148
15

Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.
David M Williams, Jeffrey W Stephens. Expert Opin Pharmacother 2015
13
15


Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
J Rosenstock, C Aguilar-Salinas, E Klein, S Nepal, J List, R Chen. Curr Med Res Opin 2009
238
10

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.
Nayyar Iqbal, Artist Parker, Robert Frederich, Mark Donovan, Boaz Hirshberg. Cardiovasc Diabetol 2014
50
10



Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
M Nowicki, I Rychlik, H Haller, M L Warren, L Suchower, I Gause-Nilsson. Diabetes Obes Metab 2011
103
10

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
Ralph A DeFronzo, Miguel N Hissa, Alan J Garber, Jorge Luiz Gross, Raina Yuyan Duan, Shoba Ravichandran, Roland S Chen. Diabetes Care 2009
326
10



Metformin + saxagliptin for type 2 diabetes.
André J Scheen. Expert Opin Pharmacother 2012
16
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.